Abstract Number: 0006 • ACR Convergence 2020
Race/ethnicity Is Associated with Poor Health Outcomes Amongst Rheumatic Disease Patients Diagnosed with COVID-19 in the US: Data from the COVID-19 Global Rheumatology Alliance Physician-Reported Registry
Background/Purpose: Individuals with rheumatic disease, particularly those on immunosuppressive medications, have a higher risk of developing severe infections. However, whether these patients experience more severe…Abstract Number: 0050 • ACR Convergence 2020
Demographic Disparities in the Medically Underserved Populations of Southern California: A Rheumatology Cohort of Cytokine Release Syndrome Patients Due to COVID-19
Background/Purpose: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has led to the present coronavirus disease (COVID-19) pandemic. Multiple epidemiologic reports across the country show…Abstract Number: 0466 • ACR Convergence 2020
Dosage Modification of Immunomodulatory Medications by Rheumatology Patients in New York City During the Peak of the COVID-19 Pandemic
Background/Purpose: Due to concerns about underlying immune dysregulation and immunosuppression, patients with systemic rheumatic diseases living in COVID-19 “hot spots” may have modified their immunomodulatory…Abstract Number: 0613 • ACR Convergence 2020
Modeling the Effects of Covid-19 Protective Behaviors and Healthcare Delivery on the Health of Patients with Rheumatic Disease
Background/Purpose: COVID-19 has caused global disruptions in the management of chronic illnesses. The extent to which patients with rheumatic disease have been affected by COVID-19…Abstract Number: 0949 • ACR Convergence 2020
SLAMF7 Engagement Drives Monocyte Super-Activation in Acute and Chronic Inflammation
Background/Purpose: Monocytes orchestrate immune responses that protect against microbes but can also drive pathological inflammation and autoimmune disease. Monocytes are thought to be activated primarily…Abstract Number: 1478 • ACR Convergence 2020
A Multidisciplinary Registry of Patients with Autoinmune and Immune-Mediated Diseases with Symptomatic COVID-19 Infection from a Single Center
Background/Purpose: National health authorities reported a prevalence of SARS-CoV-2 infection around 7% of the general population in Barcelona county (1). A recent report focused on…Abstract Number: 0007 • ACR Convergence 2020
Antimalarial Drug Shortages During the COVID-19 Pandemic: Results from the Global Rheumatology Alliance Patient Experience Survey
Background/Purpose: Early in the COVID-19 pandemic, hydroxychloroquine and chloroquine were empirically promoted and used for treatment and prevention of SARS-CoV-2 infection. The repurposing of these…Abstract Number: 0051 • ACR Convergence 2020
COVID-Related Distress and Mental Health in Adult Rheumatology Patients During the COVID-19 Pandemic
Background/Purpose: The novel coronavirus disease 2019 (COVID-19) pandemic has significantly affected all aspects of society, especially in the epicenters of New York City (NYC) and…Abstract Number: 0467 • ACR Convergence 2020
Incidence of COVID-19 in Patients Treated with Infliximab Compared to Patients Treated with Rituximab
Background/Purpose: The prevalence of anti-SARS-CoV-2 IgG infection was estimated at 9.7% in the Geneva population end of April 2020. (1) Immunosuppressed patients may be at…Abstract Number: 0614 • ACR Convergence 2020
Impact of COVID-19 Pandemic on the Rheumatology Practice in Mexico: Mexican College of Rheumatology Survey
Background/Purpose: COVID-19 pandemic is an evident challenge for healthcare systems and daily clinical practice in developing countries. Particularly, chronic diseases attention has faced difficulties. The…Abstract Number: 0984 • ACR Convergence 2020
Neighborhood Deprivation and Race/Ethnicity Affects COVID-19 Risk and Severity in SLE
Background/Purpose: Disparities have been reported during the coronavirus disease (COVID-19) outbreak. Systemic lupus erythematosus (SLE) patients represent a unique group that is affected by clinical,…Abstract Number: 1497 • ACR Convergence 2020
COVID-19 in Pregnant Patients with Rheumatic Disease: Data from the COVID-19 Global Rheumatology Alliance
Background/Purpose: The impact of COVID-19 on pregnancy in patients with rheumatic disease is unknown. We describe COVID-19 outcomes in pregnant rheumatic disease patients reported to…Abstract Number: 0008 • ACR Convergence 2020
COVID-19 Infection Among Patients with Rheumatic Disease on Biologic & Targeted Therapies: A Systematic Review
Background/Purpose: Information about the outcomes of patients with rheumatic disease with SARS-CoV-2 infection is scarce. Patients with rheumatic disease on immunosuppressive medications might represent a…Abstract Number: 0069 • ACR Convergence 2020
Identification of CD13 as a Potential Cause for SARS-CoV-2-triggered Hyperinflammation and Thrombosis
Background/Purpose: The ectopeptidase CD13, which is highly expressed on stromal and myeloid cells in joints, lung and other tissues, is a known receptor for many…Abstract Number: 0468 • ACR Convergence 2020
Concerns and Health-Related Behaviors During the COVID-19 Pandemic in Patients with or Without Autoimmune Rheumatic Disease in a Large Physician Network
Background/Purpose: Patients with autoimmune rheumatic diseases (ARD) may be particularly concerned about COVID-19. We aimed to compare concerns and health-related behaviors of patients with common…
- « Previous Page
- 1
- …
- 33
- 34
- 35
- 36
- 37
- 38
- Next Page »